AustralieFrV1, Main, Exploration, bibRecord, 008B92

Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study

Identifieur interne : 008B92 ( Main/Exploration ); précédent : 008B91; suivant : 008B93

Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study

Auteurs : Oluf Dimitri Roe [Norvège] ; Jenette Creaney [Australie] ; Steinar Lundgren [Norvège] ; Erik Larsson [Norvège] ; Helmut Sandeck [Norvège] ; Paolo Boffetta [France] ; Tom Ivar Nilsen [Norvège] ; Bruce Robinson [Australie] ; Kristina Kjaerheim [Norvège]

Source :

Lung cancer [ 0169-5002 ] ; 2008.

RBID : Pascal:08-0401056

Descripteurs français

Pascal (Inist)
- Mésothéliome malin, Pathologie de l'appareil respiratoire, Facteur prédictif, Pronostic, Etude cas témoin, Immunohistochimie, Marqueur tumoral, Cancérologie, Pneumologie.

English descriptors

KwdEn :
- Cancerology, Case control study, Immunohistochemistry, Malignant mesothelioma, Pneumology, Predictive factor, Prognosis, Respiratory disease, Tumoral marker.

Abstract

Soluble mesothelin-related protein (SMRP) in serum is potentially a sensitive marker of malignant mesothelioma (MM) diagnosis and progression, and may be useful as screening marker. Mesothelin expression in tumors is regarded as a sensitive marker for diagnosis and disease progression, and is a candidate prognostic marker. Levels of SMRP, CA125 and CYFRA 21-1 in pre-diagnostic (1-30 years) serum samples from 47 mesothelioma cases and 141 matched controls were analysed. Mesothelin expression in tumors was assessed. The association between biomarker level and mesothelioma risk and survival was analysed, adjusting for asbestos exposure. Survival related to tumor mesothelin expression, age, sex, histological type, location, asbestos exposure and pre-clinical SMRP was analysed. There was no significant association between biomarker levels and mesothelioma risk when analysed as continuous variables or as tertiles. Biomarker levels <10, 10-19 and ≥20 years before diagnosis were not significantly associated to mesothelioma risk. Mesothelin expressed in >50% of tumor cells was seen in 36 of 47 (77%) tumors. Mesothelin expression in <50% of tumor cells was a significant negative prognostic marker in all cases of malignant mesothelioma (median survival=6 months vs. 12 months, hazard ratio (HR)=2.49, 95%CI 1.17-5.27), and also when only epithelial mesothelioma was analysed (median =6 months vs. 14 months, HR=2.36, 95%CI 1.07-5.22). When adjusted for age and gender, the prognosis was still dismal, but non-significant (HR=1.85, 95%CI 0.85-4.05). High age (>65 years) was an independent negative prognostic factor that was related to both mesothelin expression and asbestos exposure. Mesothelioma of the epithelial type of the peritoneum had a significantly longer survival than epithelial type in pleura and was also related to mesothelin expression.

Affiliations:

Australie, France, Norvège
Auvergne-Rhône-Alpes, Rhône-Alpes, Trøndelag, Østlandet
Lyon, Oslo, Trondheim

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 003363
to stream PascalFrancis, to step Curation: 002C89
to stream PascalFrancis, to step Checkpoint: 003074
to stream Main, to step Merge: 009488
to stream Main, to step Curation: 008B92

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study</title>
<author><name sortKey="Roe, Oluf Dimitri" sort="Roe, Oluf Dimitri" uniqKey="Roe O" first="Oluf Dimitri" last="Roe">Oluf Dimitri Roe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Oncology, St. Olavs Hospital, Trondheim University Hospital</s1>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Department of Oncology, St. Olavs Hospital, Trondheim University Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine</s1>
<s2>Trondheim</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<placeName><settlement type="city">Trondheim</settlement>
<region type="région" nuts="2">Trøndelag</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Creaney, Jenette" sort="Creaney, Jenette" uniqKey="Creaney J" first="Jenette" last="Creaney">Jenette Creaney</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>School of Medicine and Pharmacology, University of Western Australia, QfEII Medical Centre Nedlands</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Perth, Western Australia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lundgren, Steinar" sort="Lundgren, Steinar" uniqKey="Lundgren S" first="Steinar" last="Lundgren">Steinar Lundgren</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Oncology, St. Olavs Hospital, Trondheim University Hospital</s1>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Department of Oncology, St. Olavs Hospital, Trondheim University Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine</s1>
<s2>Trondheim</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<placeName><settlement type="city">Trondheim</settlement>
<region type="région" nuts="2">Trøndelag</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Larsson, Erik" sort="Larsson, Erik" uniqKey="Larsson E" first="Erik" last="Larsson">Erik Larsson</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Norwegian University of Science and Technology (NTNU), Department of Laboratory Medicine, Children's and Women's Health</s1>
<s2>Trondheim</s2>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<placeName><settlement type="city">Trondheim</settlement>
<region type="région" nuts="2">Trøndelag</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sandeck, Helmut" sort="Sandeck, Helmut" uniqKey="Sandeck H" first="Helmut" last="Sandeck">Helmut Sandeck</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital</s1>
<s3>NOR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Boffetta, Paolo" sort="Boffetta, Paolo" uniqKey="Boffetta P" first="Paolo" last="Boffetta">Paolo Boffetta</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>International Agency for Research on Cancer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nilsen, Tom Ivar" sort="Nilsen, Tom Ivar" uniqKey="Nilsen T" first="Tom Ivar" last="Nilsen">Tom Ivar Nilsen</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Norwegian University of Science and Technology (NTNU), Human Movement Science Programme</s1>
<s3>NOR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Norwegian University of Science and Technology (NTNU), Human Movement Science Programme</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Robinson, Bruce" sort="Robinson, Bruce" uniqKey="Robinson B" first="Bruce" last="Robinson">Bruce Robinson</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>School of Medicine and Pharmacology, University of Western Australia, QfEII Medical Centre Nedlands</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Perth, Western Australia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kjaerheim, Kristina" sort="Kjaerheim, Kristina" uniqKey="Kjaerheim K" first="Kristina" last="Kjaerheim">Kristina Kjaerheim</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>The Cancer Registry of Norway</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<placeName><settlement type="city">Oslo</settlement>
<region nuts="2">Østlandet</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0401056</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0401056 INIST</idno>
<idno type="RBID">Pascal:08-0401056</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003363</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002C89</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003074</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003074</idno>
<idno type="wicri:doubleKey">0169-5002:2008:Roe O:mesothelin:related:predictive</idno>
<idno type="wicri:Area/Main/Merge">009488</idno>
<idno type="wicri:Area/Main/Curation">008B92</idno>
<idno type="wicri:Area/Main/Exploration">008B92</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study</title>
<author><name sortKey="Roe, Oluf Dimitri" sort="Roe, Oluf Dimitri" uniqKey="Roe O" first="Oluf Dimitri" last="Roe">Oluf Dimitri Roe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Oncology, St. Olavs Hospital, Trondheim University Hospital</s1>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Department of Oncology, St. Olavs Hospital, Trondheim University Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine</s1>
<s2>Trondheim</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<placeName><settlement type="city">Trondheim</settlement>
<region type="région" nuts="2">Trøndelag</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Creaney, Jenette" sort="Creaney, Jenette" uniqKey="Creaney J" first="Jenette" last="Creaney">Jenette Creaney</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>School of Medicine and Pharmacology, University of Western Australia, QfEII Medical Centre Nedlands</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Perth, Western Australia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lundgren, Steinar" sort="Lundgren, Steinar" uniqKey="Lundgren S" first="Steinar" last="Lundgren">Steinar Lundgren</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Oncology, St. Olavs Hospital, Trondheim University Hospital</s1>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Department of Oncology, St. Olavs Hospital, Trondheim University Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine</s1>
<s2>Trondheim</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<placeName><settlement type="city">Trondheim</settlement>
<region type="région" nuts="2">Trøndelag</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Larsson, Erik" sort="Larsson, Erik" uniqKey="Larsson E" first="Erik" last="Larsson">Erik Larsson</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Norwegian University of Science and Technology (NTNU), Department of Laboratory Medicine, Children's and Women's Health</s1>
<s2>Trondheim</s2>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<placeName><settlement type="city">Trondheim</settlement>
<region type="région" nuts="2">Trøndelag</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sandeck, Helmut" sort="Sandeck, Helmut" uniqKey="Sandeck H" first="Helmut" last="Sandeck">Helmut Sandeck</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital</s1>
<s3>NOR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Boffetta, Paolo" sort="Boffetta, Paolo" uniqKey="Boffetta P" first="Paolo" last="Boffetta">Paolo Boffetta</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>International Agency for Research on Cancer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nilsen, Tom Ivar" sort="Nilsen, Tom Ivar" uniqKey="Nilsen T" first="Tom Ivar" last="Nilsen">Tom Ivar Nilsen</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Norwegian University of Science and Technology (NTNU), Human Movement Science Programme</s1>
<s3>NOR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Norwegian University of Science and Technology (NTNU), Human Movement Science Programme</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Robinson, Bruce" sort="Robinson, Bruce" uniqKey="Robinson B" first="Bruce" last="Robinson">Bruce Robinson</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>School of Medicine and Pharmacology, University of Western Australia, QfEII Medical Centre Nedlands</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Perth, Western Australia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kjaerheim, Kristina" sort="Kjaerheim, Kristina" uniqKey="Kjaerheim K" first="Kristina" last="Kjaerheim">Kristina Kjaerheim</name>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>The Cancer Registry of Norway</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Norvège</country>
<placeName><settlement type="city">Oslo</settlement>
<region nuts="2">Østlandet</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Lung cancer</title>
<title level="j" type="abbreviated">Lung cancer</title>
<idno type="ISSN">0169-5002</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Lung cancer</title>
<title level="j" type="abbreviated">Lung cancer</title>
<idno type="ISSN">0169-5002</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cancerology</term>
<term>Case control study</term>
<term>Immunohistochemistry</term>
<term>Malignant mesothelioma</term>
<term>Pneumology</term>
<term>Predictive factor</term>
<term>Prognosis</term>
<term>Respiratory disease</term>
<term>Tumoral marker</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Mésothéliome malin</term>
<term>Pathologie de l'appareil respiratoire</term>
<term>Facteur prédictif</term>
<term>Pronostic</term>
<term>Etude cas témoin</term>
<term>Immunohistochimie</term>
<term>Marqueur tumoral</term>
<term>Cancérologie</term>
<term>Pneumologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Soluble mesothelin-related protein (SMRP) in serum is potentially a sensitive marker of malignant mesothelioma (MM) diagnosis and progression, and may be useful as screening marker. Mesothelin expression in tumors is regarded as a sensitive marker for diagnosis and disease progression, and is a candidate prognostic marker. Levels of SMRP, CA125 and CYFRA 21-1 in pre-diagnostic (1-30 years) serum samples from 47 mesothelioma cases and 141 matched controls were analysed. Mesothelin expression in tumors was assessed. The association between biomarker level and mesothelioma risk and survival was analysed, adjusting for asbestos exposure. Survival related to tumor mesothelin expression, age, sex, histological type, location, asbestos exposure and pre-clinical SMRP was analysed. There was no significant association between biomarker levels and mesothelioma risk when analysed as continuous variables or as tertiles. Biomarker levels <10, 10-19 and ≥20  years before diagnosis were not significantly associated to mesothelioma risk. Mesothelin expressed in >50% of tumor cells was seen in 36 of 47 (77%) tumors. Mesothelin expression in <50% of tumor cells was a significant negative prognostic marker in all cases of malignant mesothelioma (median survival=6 months vs. 12 months, hazard ratio (HR)=2.49, 95%CI 1.17-5.27), and also when only epithelial mesothelioma was analysed (median =6 months vs. 14 months, HR=2.36, 95%CI 1.07-5.22). When adjusted for age and gender, the prognosis was still dismal, but non-significant (HR=1.85, 95%CI 0.85-4.05). High age (>65 years) was an independent negative prognostic factor that was related to both mesothelin expression and asbestos exposure. Mesothelioma of the epithelial type of the peritoneum had a significantly longer survival than epithelial type in pleura and was also related to mesothelin expression.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
<li>Norvège</li>
</country>
<region><li>Auvergne-Rhône-Alpes</li>
<li>Rhône-Alpes</li>
<li>Trøndelag</li>
<li>Østlandet</li>
</region>
<settlement><li>Lyon</li>
<li>Oslo</li>
<li>Trondheim</li>
</settlement>
</list>
<tree><country name="Norvège"><noRegion><name sortKey="Roe, Oluf Dimitri" sort="Roe, Oluf Dimitri" uniqKey="Roe O" first="Oluf Dimitri" last="Roe">Oluf Dimitri Roe</name>
</noRegion>
<name sortKey="Kjaerheim, Kristina" sort="Kjaerheim, Kristina" uniqKey="Kjaerheim K" first="Kristina" last="Kjaerheim">Kristina Kjaerheim</name>
<name sortKey="Larsson, Erik" sort="Larsson, Erik" uniqKey="Larsson E" first="Erik" last="Larsson">Erik Larsson</name>
<name sortKey="Lundgren, Steinar" sort="Lundgren, Steinar" uniqKey="Lundgren S" first="Steinar" last="Lundgren">Steinar Lundgren</name>
<name sortKey="Lundgren, Steinar" sort="Lundgren, Steinar" uniqKey="Lundgren S" first="Steinar" last="Lundgren">Steinar Lundgren</name>
<name sortKey="Nilsen, Tom Ivar" sort="Nilsen, Tom Ivar" uniqKey="Nilsen T" first="Tom Ivar" last="Nilsen">Tom Ivar Nilsen</name>
<name sortKey="Roe, Oluf Dimitri" sort="Roe, Oluf Dimitri" uniqKey="Roe O" first="Oluf Dimitri" last="Roe">Oluf Dimitri Roe</name>
<name sortKey="Sandeck, Helmut" sort="Sandeck, Helmut" uniqKey="Sandeck H" first="Helmut" last="Sandeck">Helmut Sandeck</name>
</country>
<country name="Australie"><noRegion><name sortKey="Creaney, Jenette" sort="Creaney, Jenette" uniqKey="Creaney J" first="Jenette" last="Creaney">Jenette Creaney</name>
</noRegion>
<name sortKey="Robinson, Bruce" sort="Robinson, Bruce" uniqKey="Robinson B" first="Bruce" last="Robinson">Bruce Robinson</name>
</country>
<country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Boffetta, Paolo" sort="Boffetta, Paolo" uniqKey="Boffetta P" first="Paolo" last="Boffetta">Paolo Boffetta</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008B92 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008B92 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:08-0401056
   |texte=   Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study

Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri